Denmark· DK-28106551420
Pazopanib "Stada"
A pazopanib product containing pazopanib hydrochloride, registered in Denmark by STADA Arzneimittel AG. The same ATC class is registered in 14 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Pazopanib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EX03 (pazopanib), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 8 of them publish a price we can compare per daily dose
Pazopanib · ATC L01EX03
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pazopanib costs, country by country.
Normalised to the WHO defined daily dose (0.8 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Pazopanib · price per daily dose (0.8 g)
USD · FX 28 Sept 2026
- CH Switzerland$87.69
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Pazopanib hydrochloride
- Manufacturer
- STADA Arzneimittel AG
- Country
- Denmark (DK)
- ATC code
- L01EX03
- ATC class
- Pazopanib
- Defined daily dose
- 0.8 g, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106551420
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
593 interactions on record for pazopanib.
Graded by severity as the source publishes them — 155 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pazopanib · interactions on record
593 records
- 155 severe
- 428 moderate
- 10 minor
Most severe, free to view
- CimetidineA02BA01severe
- RanitidineA02BA02severe
- FamotidineA02BA03severe
- NizatidineA02BA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01EX03
Pazopanib, as other registers publish it.
- United StatespazopanibTorrent Pharmaceuticals Limited
- United StatespazopanibNovugen Pharma (USA) LLC.
- United StatesPazopanibAvKARE
- United StatesPazopanibSUN PHARMACEUTICAL INDUSTRIES, INC.
- United StatesPazopanibTeva Pharmaceuticals, Inc.
- United StatesPazopanibApotex Corp.
- United StatesPazopanibApotex Corp.
- United StatesPazopanibGolden State Medical Supply, Inc.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/af26212f-6c06-40db-bc92-05f76ebbec97 GET /v1/drugs/af26212f-6c06-40db-bc92-05f76ebbec97?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "filmovertrukne tabletter",
"source": "dkma",
"strength": "400 mg",
"auth_role": "CMS",
"dk_drugid": "28106551420",
"substance": "Pazopanib hydrochloride",
"auth_procedure": "Decentral procedure",
"in_medicinpriser": false,
"registration_date_serial": "45177"
}See everything about pazopanib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.